FDEVs reduce pro-inflammatory cytokines (IL-1β, IL-6) and increase anti-inflammatory IL-10 levels, demonstrating efficacy in mouse models of inflammatory bowel disease. Here, IL1B is linked to inflammatory bowel disease.